SLC5A2 and prediabetes syndrome: Ever use of metformin, insulin, sulfonylureas, DPP‐4 inhibitors, and SGLT‐2 inhibitors was associated with worse overall survival compared to patients who did not develop prediabetes/diabetes (Table 3).